What We Do
We find, invest in, and build innovative companies in the biomedical industry. ETP Capital supports our portfolio companies facilitate strategic alliances including cross-border partnerships, recruit management, and acquire new products and technologies to accelerate growth globally.
A key factor enabling success in the biotechnology industry is the partnership of experienced management, world-class science, and financing. ETP Capital partners with leading scientific and business visionaries, leveraging industry connections in science, clinical, regulatory, and commercialization to support business development efforts across portfolios.
To provide capital and assist management in building and commercializing breakthrough diagnostic and therapeutic products in the fields of life sciences, while providing superior returns to our investors.
About ETP Capital
Founded in 2000, Emerging Technology Partners (“ETP”) is a life sciences focused investment fund with a cross border investment focus.
Learn more about our Investment Philosophy >
Venture & Growth
We invest as early as the seed stage and as late as post-IPO rounds. ETP is comfortable acting as a lead investor or partner in syndicated rounds where the key elements for success are already in place.
ETP China was established in 2017 with the same mission to bring biomedical innovations to the world.
Human Longevity, Inc. is committed to accelerating living to 100+ by revolutionizing the landscape of the current system of “sickcare” to true “healthcare”. By continually adding and analyzing our client’s health data, we are transforming treatment from a reactive practice to one that is proactive, preventative, and personalized.
Genetron Holdings Limited (“Genetron Health” or the “Company”) is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment.
CASI Pharmaceuticals, Inc. is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products. CASI has built a portfolio that includes approved and investigational assets. We have offices in Rockville, Maryland, and a wholly-owned subsidiary in Beijing, China, through which our China operations are conducted.